cisplatin + gemcitabine + selumetinib

This is a combination regimen consisting of three drugs—cisplatin, gemcitabine, and selumetinib—used in the treatment of solid tumors. Cisplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and inhibiting ribonucleotide reductase. Selumetinib (also known as AZD6244 or ARRY-142886) is an oral, selective non-ATP-competitive inhibitor of MEK1/2, key kinases in the MAPK/ERK signaling pathway involved in cell proliferation and survival[1][2]. This combination targets cancer through both cytotoxic mechanisms (cisplatin and gemcitabine) and targeted inhibition of oncogenic signaling pathways (selumetinib), with potential application particularly in tumors driven by aberrant MAPK pathway activation such as those harboring KRAS or BRAF mutations[1][2].

Brand names

no unique combination brand nameselumetinib may be known as Koselugo, but not as a combination

Other names

selumetinib, cisplatin, gemcitabine combination